# JCO Precision Oncology

Source: https://onco.cc/journals/jco-precision-oncology/  
OnCo record `jco-precision-oncology` (Journal). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ASCO's journal for genomics-guided cancer care: tumour sequencing studies, biomarker-selected trials, molecular tumour board case series and real-world genomic data.

## Summary

JCO Precision Oncology is online-only and publishes analyses of large clinico-genomic datasets (AACR Project GENIE, Flatiron), basket and umbrella trial results, circulating tumour DNA studies and reports on rare fusions and resistance mutations. A good venue for the incremental evidence that connects a genomic test result to a treatment decision.

## Fields

- Kind: Journal
- Last checked: 2026-09-09
- Also known as: JCO PO; JCO Precis Oncol
- Publisher: American Society of Clinical Oncology
- Scope: precision oncology
- Access: hybrid

## Sources

- ASCO Publications: https://ascopubs.org

## Connected records

- collections: [AACR Project GENIE](https://onco.cc/collections/genie/)
- institutions: [American Society of Clinical Oncology (ASCO)](https://onco.cc/institutions/asco/)
- key papers: [Circulating tumor DNA profiling of advanced biliary tract cancers](https://onco.cc/key-papers/paper-mody-biliary-ctdna-profiling-jco-po-2019/), [Clinical Outcomes of Molecular Tumor Boards: A Systematic Review](https://onco.cc/key-papers/paper-larson-jco-precis-oncol/), [Concordance in Molecular Tumor Board Case Reviews in the ASCO TAPUR Study](https://onco.cc/key-papers/paper-perez-jco-precis-oncol/), [Detecting Early Recurrence With Circulating Tumor DNA in Stage I-III Biliary Tract Cancer After Curative Resection](https://onco.cc/key-papers/paper-yu-ctdna-early-recurrence-biliary-tract-cancer-jco-po-2025/), [OncoKB: A Precision Oncology Knowledge Base](https://onco.cc/key-papers/paper-chakravarty-jco-precis-oncol/), [ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib](https://onco.cc/key-papers/paper-nct03944772-jco-precis-oncol-2025/), [Palbociclib in Patients With Non-Small-Cell Lung Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study](https://onco.cc/key-papers/paper-ahn-jco-precis-oncol/), [Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With ERBB2 Amplification or ERBB2/3 Mutations: Results From the TAPUR Study](https://onco.cc/key-papers/paper-gupta-jco-precis-oncol/), [Prospective comprehensive genomic profiling of 3,476 primary and metastatic prostate tumours](https://onco.cc/key-papers/paper-chung-comprehensive-genomic-profiling-prostate-jco-po-2019/)
- journals: [Journal of Clinical Oncology](https://onco.cc/journals/jco/)

---
JSON: https://onco.cc/api/v1/entities/jco-precision-oncology.json